Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Mark A. Schroeder, MD, H. Jean Khoury, MD FACP, Madan Jagasia, MD MS, Haris Ali, MD, Gary J. Schiller, MD, Michael Arbushites, Patricia Delaite, Ying Yan, Kathleen Rhein, Miguel-Angel Perales, MD, Yi-Bin Chen, MD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 390.

https://doi.org/10.1182/blood.V128.22.390.390

Published: 2016

Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 679.

https://doi.org/10.1182/blood.V128.22.679.679

Published: 2016

Journal Articles

Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study

Nelli Bejanyan, MD, Aleksandr Lazaryan, MD PhD MPH, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Marcos de Lima, MD, Brenda M. Sandmaier, MD, Mary M. Horowitz, MD MS, H. Jean Khoury, MD, Daniel J. Weisdorf, MD

Blood (2016) 128 (22): 684.

https://doi.org/10.1182/blood.V128.22.684.684

Published: 2016

Journal Articles

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Vamsi Kota, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Jeffrey H. Lipton, MD PhD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Fiona An, MD, Eric Leip, PhD, Rocco J. Crescenzo, DO, FACOI, Mabel Woloj, PhD, Mark Shapiro, MD PhD, H. Jean Khoury, MD FACP

Blood (2016) 128 (22): 1921.

https://doi.org/10.1182/blood.V128.22.1921.1921

Published: 2016

Journal Articles

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

H Jean Khoury, Leonard T Heffner, Jr., MD, Martha Arellano, MD, Anand P Jillella, MD, Vamsi K Kota, MD, Elliott F. Winton, MD

Blood (2015) 126 (23): 4045.

https://doi.org/10.1182/blood.V126.23.4045.4045

Published: 2015

Journal Articles

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Blood (2015) 126 (23): 4025.

https://doi.org/10.1182/blood.V126.23.4025.4025

Published: 2015

Journal Articles

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors

Vamsi K Kota, MD, Elliott F. Winton, MD, Martha Arellano, MD, Anand Jillella, Morgan L. McLemore, MD, Fuad El Rassi, MD, H Jean Khoury

Blood (2015) 126 (23): 1592.

https://doi.org/10.1182/blood.V126.23.1592.1592

Published: 2015

Journal Articles

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

H. Jean Khoury, Vamsi Kota, M.B;B.S, Martha Arellano, MD, Stephanie L Bauer, ANP, Anand P Jillella, MD, Amelia Langston, MD, Zaid Al-Kadhimi, MD, Zachariah DeFilipp, MD, Audrey S Kim, RN, Elliott F. Winton, MD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1938.

https://doi.org/10.1182/blood.V126.23.1938.1938

Published: 2015

Journal Articles

Acute Chest Syndrome Rate at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System

Fuad El Rassi, MD, Eldrida Randall, MS, Sidney F. Stein, MD, H. Jean Khoury, MD, James R. Eckman, MD, Morgan L. McLemore, MD

Blood (2015) 126 (23): 3420.

https://doi.org/10.1182/blood.V126.23.3420.3420

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

Journal Articles

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

Vamsi K Kota, MD, Amanda Redden Hathaway, MD, Bijal D. Shah, MD, Deniz Peker, MD, Ling Zhang, MD, David L. Jaye, MD, Martha Arellano, MD, H Jean Khoury, Anand P Jillella, MD, Elliott F. Winton, MD, Leonard T Heffner, Jr., MD, Uma Borate, MD

Blood (2015) 126 (23): 3762.

https://doi.org/10.1182/blood.V126.23.3762.3762

Published: 2015

Journal Articles

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Dale Bixby, MD PhD, Matthew J. Wieduwilt, MD PhD, Luke Paul Akard, MD, H. Jean Khoury, MD, Pamela S. Becker, MD PhD, Edward H. Van Der Horst, PhD, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3809.

https://doi.org/10.1182/blood.V126.23.3809.3809

Published: 2015

Journal Articles

Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia

Eric Segal, BS, Michael Martens, MS, Hai-Lin Wang, MPH, Ruta Brazauskas, PhD, Daniel Weisdorf, MD, Brenda M. Sandmaier, MD, Marcos J de Lima, MD, H. Jean Khoury, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2017.

https://doi.org/10.1182/blood.V126.23.2017.2017

Published: 2015

Journal Articles

A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma

Jonathon B. Cohen, MD, Jeffrey Switchenko, PhD, Jean L. Koff, MD, Rajni Sinha, MD MRCP, Jonathan L. Kaufman, MD, H. Jean Khoury, MD FACP, Nassoma K Bumpers, PA, Amanda Colbert, Amanda A Hutchison-Rzepka, BA, Loretta J. Nastoupil, MD, Leonard T. Heffner, MD, Amelia Langston, MD, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Christopher R. Flowers, MD

Blood (2014) 124 (21): 4432.

https://doi.org/10.1182/blood.V124.21.4432.4432

Published: 2014

Journal Articles

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

Carlo Gambacorti-Passerini, MD, H. Jean Khoury, Hagop M. Kantarjian, MD, Jeffrey H. Lipton, MD PhD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Ewa M. Matczak, MD, Eric Leip, PhD, Kay Noonan, Tim H. Brümmendorf, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 4559.

https://doi.org/10.1182/blood.V124.21.4559.4559

Published: 2014

Journal Articles

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, MD, Carlo Gambacorti-Passerini, Stuart L Goldberg, Jorge E. Cortes, H. Jean Khoury, MD, Mauricette Michallet, MD PhD, Ronald Paquette, MD, Bengt Simonsson, MD PhD, Michelle P Turner, MS in Biostatistics, Hesham Mohamed, MD, Milayna Subar, MD, Teresa Zyczynski, Pharm.D., MPH

Blood (2014) 124 (21): 3151.

https://doi.org/10.1182/blood.V124.21.3151.3151

Published: 2014

Journal Articles

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Blood (2014) 124 (21): 3135.

https://doi.org/10.1182/blood.V124.21.3135.3135

Published: 2014

Journal Articles

Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Mirjana Zeremski, MD, Mark Shapiro, MD, Eric Leip, PhD, Carlo Gambacorti-Passerini, MD, Jeffrey H. Lipton, MD PhD

Blood (2014) 124 (21): 5544.

https://doi.org/10.1182/blood.V124.21.5544.5544

Published: 2014

NARROW

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

A Phase I Trial of Janus Kinase (JAK) Inhibition with INCB039110 in Acute Graft-Versus-Host Disease (aGVHD)

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Single US Center Experience

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Who Switch to Imatinib Following Optimal Response to Second Generation Tyrosine Kinase Inhibitors

Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)

Acute Chest Syndrome Rate at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Poor Outcomes with Hyper CVAD Induction for T-Cell Lymphoblastic Leukemia/Lymphoma

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia

A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)

Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial

Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only